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SUMMARY
Since 2001 hepatitis B vaccination has been oﬀered to prisoners on reception into prisons in
England and Wales. However, short campaigns of vaccinating the entire population of individual
prisons have achieved high vaccination coverage for limited periods, suggesting that short
campaigns may be a preferable way of vaccinating prisoners. A model is used that describes the
ﬂow of prisoners through prisons stratiﬁed by injecting status to compare a range of vaccination
scenarios that describe vaccination on prison reception or via regular short campaigns. Model
results suggest that vaccinating on prison reception can capture a greater proportion of the
injecting drug user (IDU) population than the comparable campaign scenarios (63% vs. 55.6%
respectively). Vaccination on prison reception is also more eﬃcient at capturing IDUs for
vaccination than vaccination via a campaign, although vaccination via campaigns may have a
role with some infections for overall control.
INTRODUCTION
Injecting drug users (IDUs) are at increased risk of
infection from hepatitis B (HBV) compared to non-
IDUs. In England and Wales the prevalence of HBV
core antibody amongst current IDUs is 21% [1],
compared to 0.3% in the general population of the
United Kingdom [2].
IDUs are at high risk of incarceration with >70%
of IDUs aged >40 years in England and Wales re-
porting a previous spell of imprisonment [3], while
IDUs spend less time in prison during each period of
incarceration compared to non-IDUs [3, 4]. A high
proportion of prisoners (24% [3]) have been found to
have previously injected illicit drugs [3, 5, 6] with the
prevalence of HBV core antibody among prisoners in
England and Wales being 8% [3].
Since 2001 HBV vaccination has been oﬀered
to prisoners on reception into selected prisons in
England and Wales. For prisoners aged o18 years a
super-accelerated schedule has been implemented
with vaccine doses administered at 0, 7, and 21 days
while for those aged <18 years, doses are adminis-
tered at 0, 1, and 2 months. For all ages, where
possible, a booster dose 12 months after the ﬁrst
dose is oﬀered, with no pre- or post-test vaccination
antibody titre tests being undertaken. In recent years
the coverage has increased and in 2005 about
15% of prisoners on reception into prisons in
England and Wales were oﬀered HBV vaccination
(unpublished data from the prison HBV vaccination
monitoring programme of England and Wales :
Health Protection Agency Prison Infection Preven-
tion Team).
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Short campaigns of vaccinating prisoners across
individual prisons have achieved high vaccination
coverage for limited periods in attempts to interrupt
community-based outbreaks of hepatitis A [7, 8].
Periodic short campaigns may be a preferable way of
vaccinating prisoners instead of oﬀering vaccination
on reception into prisons.
How should vaccination be administered in a
prison setting? The objective of this study is to com-
pare the impact of vaccinating continuously on re-
ception into prison with a strategy of vaccinating the
whole of the prison population periodically (a pulse
vaccination strategy). These proposed strategies will
be compared by considering the proportion of the
IDU population vaccinated over time, the number of
doses of vaccine required to administer each scenario,
and the proportion of doses of vaccine that are
administered to IDUs.
METHODS
Model structure
The model applied here has been described in a
previous study [4]. Brieﬂy, a model has been
developed to assess the potential impact of the HBV
vaccination programme on the coverage of prisoners,
ex-prisoners and IDUs. The model describes non-
IDUs and IDUs as they ﬂow in and out of prisons in
England andWales and start and stop injecting drugs.
The model is stratiﬁed by injecting status (never
injected, current injector, past injector), imprison-
ment status (never imprisoned, currently imprisoned,
previously imprisoned), vaccination status (0, 1, 2, or
o3 doses received) and age (Fig. 1). The coverage of
the vaccination programmes at reception or via a
campaign is entered as an input into the model, with
the model outputs including the vaccination status
of IDUs and the number of vaccine doses used
over time.
Prison vaccination scenarios
The prison vaccination scenarios here consider what
proportion of individuals participate in the vacci-
nation programme either on reception into prison,
or via a pulse in which a proportion of the prison
population is vaccinated at a speciﬁc time point.
During the period 2002–2005 vaccination was
administered to prisoners on reception into prisons in
England and Wales. Data collected as part of prison
surveillance in England and Wales in 2003–2005
is used to guide the coverage estimates during this
period. For all vaccination scenarios applied here
these values are used to describe the vaccination
coverage on reception into prison during this period
with a ‘best guess ’ estimate being taken for the 2002
value. From data taken from a previous study [9] it is
assumed that for individuals on reception into prison
who participate in the programme; 38% receive a
single dose, 28% receive two doses, and 34% the
complete three-dose schedule [4] unless wasted doses
are administered (see below). This reﬂects the possi-
bility that prisoners may leave prison before having
the chance to receive all three doses of vaccine.
To allow for additional vaccination being applied
in the community, the community vaccination rate
is assumed to be 0.1/IDU per year [4]. For clarity of
exposition this is assumed to be constant from 2002
onwards.
HBV vaccination schedules typically include a
fourth booster dose administered 12 months after the
third dose, this has not been considered here as most
prisoners will leave prison before being eligible for a
fourth dose. Instead it is assumed that three doses
constitute a complete course of vaccination. To reﬂect
the possibility that due to inaccurate record keeping
or recall issues some individuals may be given
unnecessary doses of vaccine it is assumed for all
scenarios that 10% of individuals that have already
received three doses of vaccine that participate in the
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Fig. 1. Flow diagram of the turnover of prisoners in
England and Wales [including injecting drug users (IDUs)].
The mutually exclusive compartments represent the diﬀer-
ent imprisonment and IDU states. Arrows represent the
ﬂow between the states. (X are individuals that have never
been imprisoned, Y is the prison population, and Z are
individuals previously imprisoned. N are those individuals
that have never injected while I and P denote current and
previous IDUs respectively). This structure is further
stratiﬁed by age 15–74 years. The rates that individuals
move between compartments may be age-dependent.
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programme will accept an additional unnecessary
dose.
Continuous scenarios
Four alternative prison vaccination scenarios that
describe vaccination coverage on reception into
prisons in England and Wales are investigated.
Taking coverage values from 2002 to 2005 at 5%,
7.5%, 10% and 15%, these scenarios consider the
impact of varying levels of vaccination coverage on
receptions into prison over time. Each continuous
vaccination scenario assumes an alternative constant
vaccination coverage from 2006 onwards of 30%,
50%, 80% and 100% respectively.
Pulse vaccination scenarios
For the pulse vaccination scenarios it is assumed from
2006 onwards that all vaccination on reception into
prisons in England and Wales is ceased, and instead a
policy of periodically vaccinating the entire prison
population is adopted in addition to community
vaccination. It is assumed for each pulse scenario that
a pulse is delivered to a proportion of the prison
population (30%, 50%, 80%, and 100%) at a given
frequency (every 3 months, 6 months, 1 year and 2
years). Pulses are assumed to be implemented instan-
taneously with the same proportions of those oﬀered
vaccine receiving one, two or three doses as in the
continuous scenarios, again this is because some
individuals may leave prison before receiving three
doses of vaccine. This approach does ensure greater
comparability between the pulse and continuous
scenarios. However, it is acknowledged that prisoners
that are vaccinated in prison will be further into their
prison sentences and therefore more likely to leave
prison before receiving a complete course of vacci-
nations compared to prisoners vaccinated on reception
into prison.
Scenario eﬃciency
IDUs are at increased risk from HBV infection com-
pared to non-IDUs. To make a comparable measure
between the eﬃciency of each scenario the proportion
of the doses of vaccine that are administered to IDUs
is considered.
RESULTS
Proportion of the IDU population vaccinated over
time
Figure 2 shows a comparison between the continuous
vaccination scenarios and the pulse scenarios im-
plemented 3 months apart. The continuous scenarios
capture a greater proportion of the IDU population
than the comparable pulse scenario in each case. For
example implementing the 80% continuous scenario
may lead to >60% of the IDU population being
vaccinated compared to<55% for the 80% 3-month
pulse scenario.
Figure 3 shows the vaccination status of the
IDU population in 2012 for each of the pulse and
continuous vaccination scenarios considered here.
Oﬀering vaccine to 100% of prisoners on reception
into prison (continuous scenario) captures the great-
est proportion of the IDU population with vaccine
(o2 doses). In all cases the continuous scenario
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Fig. 2. Vaccination status of the injecting drug user (IDU) population over time under the continuous and pulse vaccination
scenarios in which pulses are administered 3 months apart.
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captures a greater proportion of the IDU population
than the comparable (same percentage of prisoners
oﬀered vaccine) pulse scenario.
Number of doses required to implement each
proposed scenario over time
An important consideration when comparing vacci-
nation scenarios is the number of vaccination doses
required to implement each scenario. From 2002 to
2005 the number of vaccination doses required is the
same for each vaccination scenario, therefore only the
number of doses required from 2006 to 2012 are
considered here (Fig. 4a). The continuous scenarios
require a greater number of doses than the pulse
scenarios with the exception of pulse scenarios that
are 3 months apart and have coverage of 80–100%
(Fig. 4a).
Vaccination scenario eﬃciency
Taking the deﬁnition of scenario eﬃciency to be the
proportion of doses of vaccine administered to IDUs,
the eﬃciency of each scenario in 2012 is shown in
Figure 4b. In all cases the continuous scenarios are
considerably more eﬃcient at capturing IDUs for
vaccination than the pulse scenarios. For the pulse
scenarios it can be seen that they become more
eﬃcient at vaccinating IDUs if they can be im-
plemented with high coverage.
Age-speciﬁc vaccination coverage
Figure 4c shows the age-speciﬁc vaccination coverage
in 2012 for the 100% continuous and 100% 3-month
pulse scenarios. These scenarios have been chosen as
they have been shown to be the most eﬃcient at
capturing IDUs for vaccination (Fig. 4b). The 100%
continuous vaccination scenario captures a greater
percentage of younger IDUs than the 100% 3-month
pulse scenario. In both cases the age-speciﬁc percent-
age of the IDU population receiving o2 doses of
vaccine increases with age.
Wasted doses
Figure 4d shows what percentage of doses adminis-
tered are given to individuals unnecessarily. In all
cases the pulse vaccination scenarios waste more
doses of vaccine than the continuous vaccination
scenarios; the shorter the length of time between the
pulses, the greater the wastage leading to many fully
vaccinated individuals being exposed to repeated
vaccination, this is due to there being less turnover of
the prison population between pulses.
DISCUSSION
It has been established elsewhere that prison provides
a good location in which to vaccinate IDUs for HBV
[4, 10–12]. The work here investigates whether it is
preferable to oﬀer HBV vaccination on reception into
prisons, or whether the whole prison population
should be periodically vaccinated by means of a
vaccination campaign (pulse vaccination scenario).
The work here makes a number of comparisons be-
tween a range of alternative hypothetical vaccination
scenarios considering the percentage of the IDU
population receivingo2 doses of vaccine, the number
of doses required to administer each scenario, and the
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Fig. 3. Vaccination status of the injecting drug user (IDU) population in 2012 with variations in vaccination scenario. (For
the 2-year pulses due to the oscillations of the vaccination coverage an average over 2011 and 2012 is taken.)
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eﬃciency of each scenario in terms of the proportion
of vaccine doses administered to IDUs.
The present study shows that vaccinating on re-
ception into prisons captures a higher proportion
of the IDU population for vaccine than vaccinating
the prison population periodically via a pulse.
Considering the number of doses over time required
to implement each vaccination scenario and the
number of IDUs that are vaccinated allows us to
measure the eﬃciency of each scenario at capturing
the IDU population with vaccine. In all cases it was
found that the continuous vaccination scenarios were
more eﬃcient at vaccinating IDUs than the pulse
scenarios. It has been found in previous studies that
IDUs are typically given shorter prison sentences
compared to non-IDUs [3, 4, 13]. A consequence of
this is that there will be a greater proportion IDUs on
reception into prison than in the prison population
itself and hence reception will provide a better
location in which to capture IDUs with vaccine.
Previous studies have shown that younger IDUs
with shorter injecting career lengths are at increased
risk of blood-borne virus infection compared to more
experienced IDUs [14]. Therefore it is of interest to
consider whether a pulse or continuous vaccination
strategy would be better at capturing younger IDUs
for vaccination. The present study shows that when
comparing the pulse and continuous vaccination
scenarios that are most eﬃcient at capturing the
IDU population for vaccination (100% continuous
and 100% 3-month pulse) (Fig. 4c) the continuous
scenario captures a greater proportion of younger
IDUs than the pulse scenario. This suggests that
continuous vaccination on prison reception may also
have a greater impact on the transmission of HBV
compared to a pulse vaccination strategy.
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Fig. 4. (a) Number of doses required to implement each vaccination scenario from 2006 to 2012. (b) Percentage of doses (ﬁrst,
second, third doses) given to under-vaccinated injecting drug users (IDUs) in 2012 with variation in the vaccination scenario.
(c) The age-speciﬁc percentage of the IDU population receiving o2 doses of vaccine in 2012 when applying the 100%
continuous and 100% 3-month pulse scenario. (d ) Percentage of doses that are administered unnecessarily with variation
in the vaccination scenario. Key (panels a, b, d ) : &, Continuous ; %, 3-month pulse ; , 6-month pulse ; , 1-year pulse ;
, 2-year pulse.
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The model used here describes the ﬂow of IDUs
and non-IDUs through prisons in England and Wales
and reﬂects the diﬀering oﬀending characteristics
of IDUs and non-IDUs. However, this model used
an extensive survey of prisoners that was undertaken
in 1997, and no survey of comparable size giving
detailed data on the oﬀending characteristics of IDUs
in England and Wales has been undertaken since. If
the oﬀending characteristics of IDUs have changed
since 1997 then this will not be reﬂected in the mod-
elling work presented here, however, as data become
available the model here can be re-parameterized to
incorporate this new information.
The present study shows that vaccinating prisoners
against HBV on reception into prison is preferable
to periodically vaccinating the whole of prison
population via a pulse. Vaccinating on reception into
prison captures a greater proportion of the IDU
population with vaccine, is more eﬃcient at vacci-
nating the IDU population, and wastes less doses of
vaccine than a pulse vaccination strategy. However,
it should be noted that vaccinating on prison recep-
tion requires more doses of vaccine than a pulse
vaccination campaign.
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